相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor α positive breast cancer
Muralidharan Anbalagan et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer
Hideo Inaji et al.
CANCER SCIENCE (2012)
Randomized Phase II Trial of Everolimus in Combination With Tamoxifen in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer With Prior Exposure to Aromatase Inhibitors: A GINECO Study
Thomas Bachelot et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Novel Aromatase Inhibitors by Structure-Guided Design
Debashis Ghosh et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Rhodacyanine Derivative Selectively Targets Cancer Cells and Overcomes Tamoxifen Resistance
John Koren et al.
PLOS ONE (2012)
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer
Quan Jiang et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer
P. N. Munster et al.
BRITISH JOURNAL OF CANCER (2011)
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
Mohammad H. Forouzanfar et al.
LANCET (2011)
The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
Bo Yoon Chang et al.
TOXICOLOGICAL RESEARCH (2011)
Progression and treatment of HER2-positive breast cancer
April Davoli et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies
Erica L. Mayer et al.
CLINICAL CANCER RESEARCH (2010)
Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety,Tolerability, and Systemic Bioavailability in Healthy Human Subjects
A. Ahmad et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2010)
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: A potential clinical application of angiogenesis inhibitors
Roshani R. Patel et al.
EUROPEAN JOURNAL OF CANCER (2010)
Antitumor Agents. 272. Structure-Activity Relationships and In Vivo Selective Anti-Breast Cancer Activity of Novel Neo-tanshinlactone Analogues
Yizhou Dong et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Characterization of the Pharmacophore Properties of Novel Selective Estrogen Receptor Downregulators (SERDs)
Karen J. Kieser et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Third-Generation SERMs May Face Uphill Battle
Charlie Schmidt
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women
Andrea Z. LaCroix et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Evaluation of the safety and tolerability of oral TAS-108 in postmenopausal patients with metastatic breast cancer
T. Saeki et al.
ANNALS OF ONCOLOGY (2009)
The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users
Monique J. Bijl et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Activity of Fulvestrant 500 mg Versus Anastrozole 1 mg As First-Line Treatment for Advanced Breast Cancer: Results From the FIRST Study
John F. R. Robertson et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
CYP2D6 and tamoxifen: DNA matters in breast cancer
Janelle M. Hoskins et al.
NATURE REVIEWS CANCER (2009)
Cross-talk between Notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches
Paola Rizzo et al.
CANCER RESEARCH (2008)
Effects of fulvestrant 750 mg in premenopausal women with oestrogen-receptor-positive primary breast cancer
O. E. Young et al.
EUROPEAN JOURNAL OF CANCER (2008)
Selective estrogen-receptor modulators and antihormonal resistance in breast cancer
V. Craig Jordan et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase II trial of Afimoxifene (4-hydroxytamoxifen gel) for cyclical mastalgia in premenopausal women
Robert Mansel et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators
Bryan M. Wittmann et al.
CANCER RESEARCH (2007)
Fulvestrant (Faslodex®) -: How to make a good drug better
John F. R. Robertson
ONCOLOGIST (2007)
Long-term treatment with tamoxifen facilitates translocation of estrogen receptor α out of the nucleus and enhances its interaction with EGFR in MCF-7 breast cancer cells
Ping Fan et al.
CANCER RESEARCH (2007)
Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer
Li Hua Wang et al.
CANCER CELL (2006)
Antitumor agents. 254. Synthesis and biological evaluation of novel neo-tanshinlactone analogues as potent anti-breast cancer agents
Xihong Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure
PI Moreira et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Endocrine treatment options for advanced breast cancer - the role of fulvestrant
JFR Robertson et al.
EUROPEAN JOURNAL OF CANCER (2005)
The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells
CT Freddie et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2004)
A Cancer Research (UK) randomized phase II study of idoxifene in patients with locally advanced/metastatic breast cancer resistant to tamoxifen
SRD Johnston et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2004)
Activity and safety of the antiestrogen EM-800, the orally active precursor of acolbifene, in tamoxifen resistant breast cancer
F Labrie et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Characterization of new estrogen receptor destabilizing compounds:: Effects on estrogen-sensitive and tamoxifen-resistant breast cancer
J Hoffmann et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor
LH Wang et al.
NATURE MEDICINE (2004)
Antitumor agents.: 239.: isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza
XH Wang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2004)
Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance
R Schiff et al.
CLINICAL CANCER RESEARCH (2004)
Both N- and C-terminal transactivation functions of DNA-bound ERα are blocked by a novel synthetic estrogen ligand
Y Yamamoto et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2003)
Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients
J Baselga et al.
ANNALS OF ONCOLOGY (2003)
Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells
IR Hutcheson et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
Drug therapy: Aromatase inhibitors in breast cancer
IE Smith et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 1. Receptor interactions
VC Jordan
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Effects of raloxifene after tamoxifen on breast and endometrial tumor growth in athymic mice
RM O'Regan et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate
A Buzdar et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: Results of a phase III randomized double-blind trial
M Kaufmann et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
